From Vendor to Partner: Codon Devices Inks First Deal | GenomeWeb

Formed in late 2004, Codon Devices is still a relative newcomer to the field. But that hasn’t stopped it from shooting to be a leader in the gene synthesis industry — and with a recent deal with ag biotech Agrivida under its belt, the startup is certainly taking steps toward that goal.

With co-founders including George Church, Drew Endy, Jay Keasling, and Joseph Jacobson, it’s no wonder Codon already has a bevy of customers and has also played a critical role in trying to shape the education and regulatory environment surrounding gene synthesis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.